Literature DB >> 22644590

New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.

Christophe Duret1, Nathalie Wauthoz, Thami Sebti, Francis Vanderbist, Karim Amighi.   

Abstract

PURPOSE: Novel itraconazole (ITZ)-based dry powders for inhalation (DPI) were optimized for aerodynamic and dissolution properties and contained excipients that are acceptable for inhalation.
METHODS: The DPI were produced by spray drying solutions. The drug content, crystallinity state, and morphological evaluation of the dry powders were determined by high performance liquid chromatography, powder X-ray diffraction, differential scanning calorimetry, and scanning electron microscopy, respectively. A particle size analysis was conducted using laser light scattering. The aerodynamic behaviors of the powders were characterized by impaction tests. ITZ dissolution rates were evaluated using a dissolution method adapted to inhaled products.
RESULTS: The DPI presented very high fine particle fractions that ranged from 46.9% to 67.0% of the nominal dose. The formulations showed very fast dissolution rates compared to unformulated crystalline ITZ with the possibility of modulating the dissolution rate by varying the quantity of phospholipids (PL) incorporated. ITZ remained amorphous while the mannitol was crystalline. The α, β and δ-mannitol polymorph ratios varied depending on the formulation compositions.
CONCLUSION: This formulation strategy could be an attractive alternative for treating invasive pulmonary aspergillosis. The ITZ and PL content are key characteristics because of their influence on the dissolution rate and aerosol performance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644590     DOI: 10.1007/s11095-012-0779-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  42 in total

1.  Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.

Authors:  Christophe Duret; Nathalie Wauthoz; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Int J Pharm       Date:  2012-03-10       Impact factor: 5.875

Review 2.  Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids.

Authors:  Birju Shah; Vasu Kumar Kakumanu; Arvind K Bansal
Journal:  J Pharm Sci       Date:  2006-08       Impact factor: 3.534

3.  In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2.

Authors:  V P Shah; Y Tsong; P Sathe; J P Liu
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

4.  Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.

Authors:  Richa Misra; Abida Malik; Sanjay Singhal
Journal:  Indian J Pathol Microbiol       Date:  2011 Jan-Mar       Impact factor: 0.740

5.  Itraconazole lung concentrations in haematological patients.

Authors:  B Coronel; J C Levron; D Dorez; A Van Devenne; E Archimbaud; A Mercatello
Journal:  Mycoses       Date:  2000       Impact factor: 4.377

6.  Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study.

Authors:  T Osaki; T Hanagiri; R Nakanishi; I Yoshino; S Taga; K Yasumoto
Journal:  Chest       Date:  1999-05       Impact factor: 9.410

7.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

8.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Aerosolization properties, surface composition and physical state of spray-dried protein powders.

Authors:  Cynthia Bosquillon; Paul G Rouxhet; François Ahimou; Denis Simon; Christine Culot; Véronique Préat; Rita Vanbever
Journal:  J Control Release       Date:  2004-10-19       Impact factor: 9.776

10.  Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

Authors:  Carlos A Alvarez; Nathan P Wiederhold; Jason T McConville; Jay I Peters; Laura K Najvar; John R Graybill; Jacqueline J Coalson; Robert L Talbert; David S Burgess; Rosie Bocanegra; Keith P Johnston; Robert O Williams
Journal:  J Infect       Date:  2007-03-13       Impact factor: 6.072

View more
  2 in total

1.  Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.

Authors:  Mohammed M Mehanna; Salma M Mohyeldin; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2019-11-22

2.  New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.

Authors:  Christophe Duret; Nathalie Wauthoz; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Int J Nanomedicine       Date:  2012-10-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.